New Drug Stunts Tumor Growth, Cylene Pharmaceuticals, Inc. Reveals
Published: Jul 18, 2012
Cancer is a leading cause of death globally. Now, researchers are breaking ground on new ways to cut off the ability for cancer cells to grow. RNA Polymerase I (Pol I) activity is essential for cancer cell survival. Scientists are discovering that its inhibition selectively activates p53 (tumor suppressor protein) to kill tumors. Cylene Pharmaceuticals, founded by Daniel Von Hoff the worlds leading clinical oncologist, has found that the Pol I inhibitor, CX-5461, selectively destroys cancer by activating p53 in malignant cells but not in normal cells.